Reference Detail

Ref Type
PMID
Authors Steven M. Horwitz, Mehdi Hamadani, Michelle A. Fanale, Jay Feingold, Alexander I Spira, Paul A Fields, Tobias Menne, Anand Karnad, Alison J. Moskowitz, Catherine Hildyard, Shui He, Joseph Boni and Graham Collins
Title Interim Results from a Phase 1 Study of ADCT-301 (Camidanlumab Tesirine) Show Promising Activity of a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
Journal Blood
Vol
Issue
Date
URL http://www.bloodjournal.org/content/130/Suppl_1/1510
Abstract Text Blood 2017 130(Suppl 1):1510

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Camidanlumab Tesirine Camidanlumab Tesirine 2 2
Drug Name Trade Name Synonyms Drug Classes Drug Description
Camidanlumab Tesirine ADCT-301 Camidanlumab Tesirine is a human nomoclonal antibody against CD25 in conjugation with pyrrolobenzodiazepine dimer toxin, which may specifically target CD25-positive tumor cells (Blood 2017 130(Suppl 1):1510).
Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown non-Hodgkin lymphoma not applicable Camidanlumab Tesirine Phase I Actionable In a Phase I trial, Camidanlumab Tesirine treatment resulted in partial response in 15.8% (3/19) in non-Hodgkin lymphoma patients (Blood 2017 130(Suppl 1):1510; NCT02432235). detail...
Unknown unknown Hodgkin's lymphoma not applicable Camidanlumab Tesirine Phase I Actionable In a Phase I trial, Camidanlumab Tesirine treatment resulted in an objective response rate of 63.6% (14/22) and a complete response rate of 27.3% (6/22) in Hodgkin's lymphoma patients (Blood 2017 130(Suppl 1):1510; NCT02432235). detail...